PINC Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 6.37% compared to Premier, Inc.'s net margin of 0.11%. Premier, Inc.'s return on equity of 0.91% beat Astrana Health, Inc.'s return on equity of 1.85%.

Premier, Inc. has a consensus price target of $28.25, signalling downside risk potential of -0.04%. On the other hand Astrana Health, Inc. has an analysts' consensus of $40.2500 which suggests that it could grow by 76.61%. Given that Astrana Health, Inc. has higher upside potential than Premier, Inc., analysts believe Astrana Health, Inc. is more attractive than Premier, Inc..

Premier, Inc. has a beta of 0.622, which suggesting that the stock is 37.797% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.

Premier, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.97%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier, Inc. pays 380.95% of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Premier, Inc. quarterly revenues are $240M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Premier, Inc.'s net income of $15.3M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, Premier, Inc.'s price-to-earnings ratio is 129.84x while Astrana Health, Inc.'s PE ratio is 119.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier, Inc. is 2.46x versus 0.39x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of 6.37% compared to Premier, Inc.'s net margin of 9.58%. Premier, Inc.'s return on equity of 0.91% beat Cryo-Cell International, Inc.'s return on equity of --.

Premier, Inc. has a consensus price target of $28.25, signalling downside risk potential of -0.04%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 115.19%. Given that Cryo-Cell International, Inc. has higher upside potential than Premier, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Premier, Inc..

Premier, Inc. has a beta of 0.622, which suggesting that the stock is 37.797% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.

Premier, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.97%. Cryo-Cell International, Inc. offers a yield of 16.46% to investors and pays a quarterly dividend of $0.15 per share. Premier, Inc. pays 380.95% of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Premier, Inc. quarterly revenues are $240M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Premier, Inc.'s net income of $15.3M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Premier, Inc.'s price-to-earnings ratio is 129.84x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier, Inc. is 2.46x versus 1.01x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners, Inc. has a net margin of 6.37% compared to Premier, Inc.'s net margin of -20.12%. Premier, Inc.'s return on equity of 0.91% beat P3 Health Partners, Inc.'s return on equity of -223.63%.

Premier, Inc. has a consensus price target of $28.25, signalling downside risk potential of -0.04%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 95.19%. Given that P3 Health Partners, Inc. has higher upside potential than Premier, Inc., analysts believe P3 Health Partners, Inc. is more attractive than Premier, Inc..

Premier, Inc. has a beta of 0.622, which suggesting that the stock is 37.797% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Premier, Inc. has a quarterly dividend of $0.21 per share corresponding to a yield of 2.97%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Premier, Inc. pays 380.95% of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.

Premier, Inc. quarterly revenues are $240M, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. Premier, Inc.'s net income of $15.3M is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, Premier, Inc.'s price-to-earnings ratio is 129.84x while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Premier, Inc. is 2.46x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.